Printer Friendly

Atypical antipsychotics in pregnancy.

While data regarding the reproductive safety of certain psychotropics such as selective serotonin reuptake inhibitors and anti-epileptic drugs have increased over the last several years, information regarding attendant risks of fetal exposure to antipsychotics remains more sparse.

This is particularly true for the newer atypical antipsychotics, which are increasingly being used in women of reproductive age for a range of psychiatric disorders in addition to schizophrenia, including bipolar disorder and depression.

It is therefore critical that clinicians and women have good information upon which to base decisions about continuing treatment during pregnancy. There are several decades' worth of data from large studies supporting the reproductive safety of the typical antipsychotics such as haloperidol or thiothixene, but the reproductive safety data for the atypical antipsychotics are extremely sparse.

To date, few prospective studies on atypicals in pregnant women have been published. In a study comparing pregnancy outcomes in 151 subjects exposed to different atypicals--60 to olanzapine, 49 to risperidone, 36 to quetiapine. and 6 to clozapine--with nonexposed controls, major malformation rates were not significantly different between the two groups (J. Clin. Psychiatry 2005;66:444-9). However, this is a relatively small sample. (The other two atypicals available are aripip-razole and ziprasidone.)

The other available safety data on atypical antipsychotics in pregnant women are derived mainly from case reports or small case series, which have not identified an increased risk for major malformations.

Most of the prospectively identified cases of exposure are to olanzapine (133), risperidone (over 500), and quetiapine (42), with very few to aripiprazole and clozapine, and possibly none to ziprasidone. In March, some of the first registry data on atypicals were reported at a meeting, from the Australian Pregnancy Registry. Among 38 pregnancies exposed to atypical antipsychotics, there were no major malformations.

The association of the atypicals with weight gain, diabetes, and hypertension raises another potential safety issue when these drugs are used during pregnancy. Weight gain and adiposity in pregnant women have also been associated with an increased risk of neural-tube defects, independent of folate status (Am. J. Psychiatry 2002;159:136-7).

As is often the case when considering the use of psychotropics during pregnancy, the specific clinical approach depends on when the patient sees the clinician.

For a patient who presents for evaluation before pregnancy on a low dose of an atypical antipsychotic as an adjunct to a mood stabilizer, it may make sense to switch to an antipsychotic for which more reproductive safety data are available, such as perphenazine. This scenario may not always be feasible, however, because many patients present when they are already pregnant. If they are well maintained, the clinician may be understandably reluctant to make changes.

Because of the absence of indicting data, we have typically maintained patients on atypical antipsychotics if they are already pregnant because of our concerns about clinical destabilization. However, we do recommend close follow-up for safety issues such as weight gain, diabetes, and hypertension during pregnancy, working collaboratively with the obstetrician. Another consideration is that, although there are no robust data clearly distinguishing differences in efficacy, there are patients who appear to derive particular benefit from an atypical antipsychotic.

Based on the limited data available, there does not appear to be a glaring reproductive safety signal for the atypicals. But given the prevalence of use of these medicines in psychiatry, we clearly need more quality data on this drug class, similar to those we have for antidepressants and antiepileptic drugs (AEDs), so that that the atypicals can be safely integrated into the treatment algorithms used during pregnancy to treat women across that spectrum of disease states.

We are establishing an atypical antipsychotic pregnancy registry at Massachusetts General Hospital that will be similar to the North American AED registry. This registry, along with other global AED registries, has produced invaluable data on the reproductive safety of antiepileptics.

We hope that data from registries and studies on atypical antipsychotics will be collected in a timely fashion and will make it possible for women and their physicians to make more informed decisions about use of this class of medicines during pregnancy.

BY LEE COHEN, M.D.

DR. COHEN directs the perinatal psychiatry program at Massachusetts General Hospital, Boston, which provides information about pregnancy and mental health at www.womensmentalhealth.org. He is a consultant to manufacturers of atypical antipsychotics.
COPYRIGHT 2008 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DRUGS, PREGNANCY, AND LACTATION
Author:Cohen, Lee
Publication:OB GYN News
Date:Apr 15, 2008
Words:719
Previous Article:Mid-pregnancy cervix length may predict risk of C-section.
Next Article:Intergenerational link found in breech delivery.
Topics:


Related Articles
Dose of caution: new antipsychotic meds produce muted benefits. (Science News This Week).
Side effects guide antipsychotic drug choices: atypicals vs. typicals.
Treatment response and compliance are rarely absolute in schizophrenia.
Meds alert: old schizophrenia drug stands up to new ones.
Off-label use of atypicals.
Antipsychotics and pregnancy.
Antipsychotics: prescribe one at a time.
FDA reverses course, approves iloperidone.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters